leuprolide and Vulvar-Neoplasms

Aggressive angiomyxoma of the vulva is a benign, slow-growing tumor originating from myxoid cells of connective tissue. The tumor is known for multiple local recurrences with a low tendency to metastasize. Only around 350 cases have been documented in the scientific literature so far.. We report a case of a 40-year-old North Indian, unmarried woman with a swelling on the left labium majora for 7 years, along with surface ulceration over the mass. Local examination showed a well-circumscribed, 8 × 8 cm pedunculated  mass arising from the left labium majora with an overlying ulcer measuring 6 cm × 4 cm. After taking informed written consent, wide local excision of the mass and surrounding margins was done under anesthesia. Histopathology was suggestive of aggressive angiomyxoma. Immunohistochemistry was done, which was positive for estrogen and progesterone receptors. Her postoperative recovery was uneventful. The patient was given three doses of gonadotropin-releasing hormone agonist (injection, leuprolide 3.75 mg) once a month. No recurrence has been reported so far on follow-up visits for 1 year.. Aggressive angiomyxoma is one of the differential diagnoses for vulvovaginal growth in a female. As the tumor is well known for local recurrences, correct diagnosis and appropriate management using a multidisciplinary approach are crucial to managing such patients.

Topics: Adult; Diagnosis, Differential; Female; Humans; Leuprolide; Myxoma; Vulva; Vulvar Neoplasms

We describe a case of a 44-year-old woman with locally advanced aggressive angiomyxoma with a novel translocation

Topics: Adaptor Proteins, Signal Transducing; Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Diagnosis, Differential; Estrogen Antagonists; Female; HMGA2 Protein; Humans; Leuprolide; Magnetic Resonance Imaging; Myxoma; Rare Diseases; Transcription Factors; Translocation, Genetic; Treatment Outcome; Vulvar Neoplasms; YAP-Signaling Proteins

An aggressive angiomyxoma of the pelvis is a locally infiltrative lesion treated with wide local excision. Recurrence is common. A potential medical treatment alternative is reported.. A 34-year-old woman presented with her second recurrence of a vulvar angiomyxoma following two prior surgical excisions. Analysis of the recurrent tumor for estrogen and progesterone receptors was strongly positive. The patient was treated with 3 months of a gonadotropin-releasing hormone (GnRH) agonist. Comparison of pre- and posttreatment magnetic resonance imaging scans showed complete radiographic resolution of the tumor. Physical examination confirmed these findings.. Medical management with a GnRH agonist may obviate the need for radical exenterative surgery for a recurrent aggressive angiomyxoma of the vulva.

Topics: Adult; Antineoplastic Agents, Hormonal; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Myxoma; Vulvar Neoplasms

Topics: Adult; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Diagnostic Errors; Female; Humans; Leuprolide; Myxoma; Neoplasm Recurrence, Local; Vulvar Neoplasms